A retrospective analysis finds that patients with lung-only metastatic pancreatic cancer have better overall survival, are ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical ...

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.

More than 70% of people diagnosed with cancer in the United States now survive for five years or more, a milestone experts ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.

The company highlighted multiple myeloma and CAR T therapies as growth drivers and announced two new US manufacturing ...

Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

Three years after launching from the lab of University of California, San Francisco chemist Jim Wells, the start-up EpiBiologics has raised $109 million in series B funding to propel its ...